Brokerages Set NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Price Target at $38.25

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) has been assigned a consensus recommendation of “Moderate Buy” from the six brokerages that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $38.25.

Several equities analysts recently issued reports on NRXP shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of NRx Pharmaceuticals in a research note on Friday, May 8th. Wall Street Zen raised shares of NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, June 14th. D. Boral Capital reaffirmed a “buy” rating and issued a $34.00 price objective on shares of NRx Pharmaceuticals in a report on Tuesday, May 5th. Ascendiant Capital Markets increased their price target on NRx Pharmaceuticals from $48.00 to $49.00 and gave the stock a “buy” rating in a research report on Monday, April 27th. Finally, HC Wainwright reissued a “buy” rating and issued a $45.00 price objective on shares of NRx Pharmaceuticals in a report on Monday, April 27th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Ethos Financial Group LLC grew its stake in NRx Pharmaceuticals by 33.6% in the 1st quarter. Ethos Financial Group LLC now owns 15,900 shares of the company’s stock valued at $34,000 after acquiring an additional 4,000 shares during the period. One Wealth Management Investment & Advisory Services LLC lifted its holdings in NRx Pharmaceuticals by 35.3% during the fourth quarter. One Wealth Management Investment & Advisory Services LLC now owns 37,873 shares of the company’s stock valued at $103,000 after purchasing an additional 9,882 shares in the last quarter. State Street Corp grew its position in shares of NRx Pharmaceuticals by 14.0% in the fourth quarter. State Street Corp now owns 86,984 shares of the company’s stock valued at $236,000 after purchasing an additional 10,700 shares during the period. Sjbenen Advisory LLC purchased a new stake in shares of NRx Pharmaceuticals during the fourth quarter worth about $41,000. Finally, Two Sigma Investments LP raised its position in shares of NRx Pharmaceuticals by 66.4% during the 3rd quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock worth $173,000 after purchasing an additional 20,880 shares during the last quarter. Hedge funds and other institutional investors own 4.27% of the company’s stock.

NRx Pharmaceuticals Stock Down 3.2%

Shares of NRXP opened at $3.63 on Tuesday. The company has a market capitalization of $131.51 million, a price-to-earnings ratio of -3.33 and a beta of 2.19. NRx Pharmaceuticals has a 52 week low of $1.62 and a 52 week high of $5.05. The stock’s 50-day moving average price is $3.97 and its 200-day moving average price is $2.86.

NRx Pharmaceuticals (NASDAQ:NRXP) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.05) by $0.01. The company had revenue of $1.07 million during the quarter, compared to analysts’ expectations of $19.43 million. As a group, equities analysts anticipate that NRx Pharmaceuticals will post -0.3 EPS for the current fiscal year.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.